<DOC>
	<DOCNO>NCT01033734</DOCNO>
	<brief_summary>This open-label study ass pharmacokinetics/pharmacodynamics safety intravenous ( iv ) Tamiflu ( oseltamivir ) 3 cohort child , age 6-12 , 3-5 1-2 year , influenza infection . Patients receive iv Tamiflu therapy 5 day ( 10 dos ) . For patient whose condition longer merit continue iv dosing , therapy may switch oral Tamiflu complete prescribe course treatment . If medically necessary , iv oral therapy Tamiflu may continue 5 additional day . Anticipated time study treatment 5 10 day .</brief_summary>
	<brief_title>A Study Intravenous Tamiflu ( Oseltamivir ) Children With Influenza</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>child , 112 year age diagnosis influenza duration influenza symptom &lt; /=96 hour prior first dose study drug evidence severe hepatic decompensation patient take probenecid within 1 week prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>